Schedule III Is Real: How the Most Consequential Week in Cannabis Business History Is Playing Out

Schedule III Is Real: How the Most Consequential Week in Cannabis Business History Is Playing Out

For years, cannabis operators have been paying more in federal taxes than almost any other industry in America — not because they're unusually profitable, but because of a single line in the tax code that forbids businesses trafficking in Schedule I controlled substances from deducting normal operating expenses. That era may now be ending. This past week, the cannabis industry crossed a threshold it has been anticipating, dreading, planning for, and waiting on for over a decade: marijuana's formal rescheduling under federal law took effect, and the downstream effects are already rippling through boardrooms, law firms, and dispensary back offices across the country.

The timeline moved fast. On April 23, 2026, the Department of Justice issued a Final Order placing cannabis "subject to a state medical marijuana license" into Schedule III of the Controlled Substances Act — the same category as anabolic steroids and ketamine. Three days later, on April 28, the order was published in the Federal Register, making it the official effective date of the rescheduling. The very next morning, the DEA opened its Medical Marijuana Dispensary Registration Portal at 9:00 AM Eastern, accepting applications that would — for the first time — bring state-licensed cannabis operations into formal federal compliance. The application fee was set at $794 per year, payable initially through PayPal, with more payment methods promised in coming weeks.

What's significant about this isn't just the symbolism. Under the Final Order's structure, operators who submit DEA registration applications within 60 days of the Federal Register publication date — meaning by approximately June 27, 2026 — will be permitted to continue operating under their existing state medical marijuana license while their federal application is under review. That's a crucial runway, and legal observers are urging state-licensed operators not to sit on it. The DEA has designed an expedited review process that accepts a valid state medical license as primary evidence of federal authorization, so the procedural lift is manageable. But missing the window carries real risk: businesses that don't apply and aren't covered by the expedited process could face a regulatory gray area that would make their federal competitors' path smoother.

The most immediately consequential change may be the one that accountants have been calling the most important story in cannabis for years: the effective dismantling of Section 280E of the Internal Revenue Code as it applies to medical cannabis. 280E was written in 1982 to prevent drug traffickers from claiming federal tax deductions, and it has been applied to state-licensed cannabis companies — legal under their own state's laws — ever since, forcing them to pay effective tax rates of 60 to 80 percent on gross income. Because Schedule III substances are no longer covered by the 280E prohibition on trafficking in Schedule I or II substances, rescheduling generally removes the law as a barrier for medical cannabis businesses. On April 23, the Treasury Department and IRS announced they will issue formal guidance to clarify the transition, including a transition rule specifying that rescheduling will be considered to first apply for a business's full taxable year that includes the effective date of the Final Order — meaning the 2026 tax year, for most businesses. For operators who have been paying punishing federal tax rates for years while watching their traditional business counterparts deduct everything from rent to employee health care, the relief is expected to be significant and immediate.

Against this backdrop, deal-making moved at pace. On April 30 — the same day the House passed the 2026 Farm Bill — Vireo Growth announced it had agreed to acquire FLUENT Corp. in an all-stock transaction. The deal, which also involves converting approximately $30 million in outstanding FLUENT debt into equity, would make Vireo the third-largest cannabis operator in medical-only Florida. FLUENT generated approximately $71.5 million in Florida revenue in 2025 and brings 74 stores and 144,000 square feet of cultivation and production canopy to the combination. Vireo would receive each FLUENT common share at a ratio of 0.0705359 Vireo subordinate voting shares, with the transaction subject to court, shareholder, and regulatory approvals in each operating state. For a market that has seen years of contraction, fire-sale consolidation, and operator bankruptcies, a structured, equity-backed deal of this size signals something important: capital is returning to cannabis, and it's returning with the confidence that the regulatory overhang is finally lifting.

Investors and financial institutions that long avoided cannabis due to its Schedule I stigma — and the banking complications that went with it — are now taking a fresh look at the sector. That doesn't mean all problems are solved. The rescheduling covers state-licensed medical cannabis, not adult-use recreational markets, and a separate, broader rescheduling proceeding is now underway that will ultimately determine whether recreational cannabis gets the same treatment. Congressional Republicans are already moving to challenge the executive's rescheduling authority, and the Senate has yet to act on the Farm Bill's hemp provisions that would reshape another major corner of the cannabis market.

But the bottom line for industry operators this week is unmistakable: the ground shifted. Businesses that have been operating in a legal limbo for years now have a credible federal compliance pathway, a near-term tax reprieve, and a landscape that looks, for the first time in a long time, like one investors want to be in.